Moderna (NASDAQ:MRNA) Shares Gap Down - Time to Sell?

Key Points

• Moderna shares plunged after a record rally: The stock opened at $150.14 after closing at $174.38 and later traded near $137.78, as profit-taking, valuation concerns and a fading short squeeze pressured shares.
• Pipeline progress strengthened Moderna’s long-term outlook: Its personalized mRNA melanoma vaccine, used with Merck’s Keytruda, met Phase 3 endpoints, while the FDA also approved its mRNA-based flu vaccine, mFLUSIVA. Further regulatory, safety and commercialization data are still needed.
• Analysts remain cautious despite the positive developments: The consensus rating is “Hold,” with an average price target of $66.25; Morgan Stanley raised its target to $89 but maintained an equal-weight rating, well below recent trading levels.

Moderna, Inc. (NASDAQ:MRNA - Get Free Report)'s stock price gapped down prior to trading on Thursday . The stock had previously closed at $174.38, but opened at $150.14. Moderna shares last traded at $137.7820, with a volume of 22,809,089 shares traded.

Key Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck reported that their Phase 3 INTerpath-001 trial met its primary and secondary endpoints. The personalized mRNA vaccine intismeran, used with Merck’s Keytruda, reduced the risk of melanoma recurrence and distant metastasis in patients with completely resected, high-risk stage IIB-IV disease—the first positive late-stage result for a personalized mRNA cancer vaccine. Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial
• Positive Sentiment: The result strengthens the investment case that Moderna’s mRNA platform can generate growth beyond COVID-19 vaccines. Analysts and investors see potential applications in other cancers, while one estimate cited possible annual intismeran sales of about $3 billion by 2035. Moderna’s Personalized Cancer Vaccine Proves Its mRNA Tech Works
• Positive Sentiment: Moderna also received FDA approval for mFLUSIVA, its first mRNA-based seasonal influenza vaccine, adding a new commercial product to its respiratory-vaccine portfolio. FDA Approves Moderna’s mFLUSIVA Seasonal Influenza Vaccine
• Neutral Sentiment: The melanoma results are topline findings; investors still need detailed efficacy and safety data, regulatory approval, and evidence that the treatment can be manufactured and commercialized profitably. Approval could come as early as 2027, according to reports.
• Negative Sentiment: After the stock more than doubled in the prior session, valuation concerns and profit-taking pressured shares. Morgan Stanley raised its price target to $89 but retained an “equal weight” rating, leaving its target materially below the market level. Moderna stock falls after record rally as valuation concerns emerge
• Negative Sentiment: The earlier surge was amplified by a short squeeze, with short sellers reportedly facing billions of dollars in paper losses. That technical buying pressure may fade, potentially increasing volatility as the stock establishes a new valuation.

Wall Street Analyst Weigh In

Several analysts have commented on MRNA shares. Morgan Stanley boosted their target price on shares of Moderna from $39.00 to $89.00 and gave the stock an "equal weight" rating in a research report on Thursday. Royal Bank Of Canada reaffirmed a "sector perform" rating and issued a $130.00 price objective on shares of Moderna in a research note on Wednesday. Loop Capital set a $135.00 price objective on shares of Moderna in a report on Wednesday. Jefferies Financial Group reissued a "hold" rating on shares of Moderna in a research report on Wednesday. Finally, Brookline Capital Markets restated a "buy" rating on shares of Moderna in a report on Wednesday. Four analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $66.25.

Moderna Price Performance

The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. The stock's 50 day moving average price is $64.91 and its two-hundred day moving average price is $54.84. The firm has a market capitalization of $55.66 billion, a price-to-earnings ratio of -17.45 and a beta of 0.91.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.03) by $0.06. The business had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. Moderna's revenue was up 2.1% compared to the same quarter last year. During the same period last year, the business posted ($2.13) EPS. On average, equities research analysts anticipate that Moderna, Inc. will post -6.18 EPS for the current year.

Insider Activity

In other Moderna news, insider Shannon Thyme Klinger sold 3,471 shares of the firm's stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total value of $173,550.00. Following the sale, the insider owned 67,468 shares of the company's stock, valued at $3,373,400. This trade represents a 4.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of the firm's stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $51.37, for a total value of $2,739,870.32. Following the completion of the sale, the president directly owned 1,483,848 shares in the company, valued at $76,225,271.76. This trade represents a 3.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 10.80% of the company's stock.

Institutional Investors Weigh In On Moderna

Several hedge funds and other institutional investors have recently modified their holdings of the stock. MUFG Securities EMEA plc acquired a new position in Moderna during the 2nd quarter valued at $28,000. Allied Private Wealth LLC acquired a new stake in Moderna in the 2nd quarter worth $30,000. Canton Hathaway LLC bought a new position in shares of Moderna during the 1st quarter worth about $31,000. Archer Investment Corp bought a new position in shares of Moderna during the 2nd quarter worth about $36,000. Finally, EverSource Wealth Advisors LLC raised its position in shares of Moderna by 148.3% during the second quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company's stock valued at $37,000 after buying an additional 801 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source